Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15008MR)

This product GTTS-WQ15008MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15008MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13993MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ1806MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ4533MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ10670MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ10963MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ10209MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ10238MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ5669MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW